News | Biogen

June 16, 2021

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential treatment for Alzheimer’s disease.

June 15, 2021

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

June 14, 2021

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

Grid View List View

May 28, 2020

Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis Four hundred students from Massachusetts and North Carolina are enrolling in this no-fee program

May 19, 2020

New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS

Patients treated with VUMERITY ® (diroximel fumarate) and TECFIDERA ® (dimethyl fumarate) showed a significant reduction of gadolinium-enhancing lesions compared to baseline Additional data show improved gastrointestinal tolerability with VUMERITY compared to TECFIDERA Further research evaluates

May 18, 2020

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adults The longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages and SMA types New data add to the significant body of evidence underscoring the clinically

May 15, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation from AAN Science Highlights Virtual Platform on May 18, 2020

Cambridge, Mass. – May 15, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a prerecorded webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming 2020 AAN Science Highlights virtual platform.

April 27, 2020

Biogen Prices $3.0 Billion of Senior Unsecured Notes

CAMBRIDGE, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the pricing of two series of senior unsecured notes for an aggregate principal amount of $3.0 billion. The notes will mature as follows: $1.5 billion will mature on May 1, 2030 and will bear interest

April 20, 2020

Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics

Continued to improve absolute environmental performance across energy, water and waste metrics while growing the business in 2019; has remained carbon neutral for six years in a row Advanced health equity and diversity goals; 46% of Biogen’s director-level positions and above are held by women

April 16, 2020

Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank

Biogen employees, family members, and other close contacts can contribute blood samples and medical data to aid efforts to rapidly understand and overcome COVID-19 Biobank to provide scientists with access to a large collection of biological and medical data to advance knowledge and search for

April 8, 2020

Biogen to Report First Quarter 2020 Financial Results April 22, 2020

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2020 financial results Wednesday, April 22, 2020, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

April 2, 2020

Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA) Well-established safety profile and proven efficacy of SPINRAZA in a broad range of patients supports exploration of the higher dose Biogen

March 30, 2020

Biogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020

Cambridge, Mass. – March 30, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming virtual AAT-AD/PDTM focus meeting. The data in this presentation were previously